NewAmsterdam Pharma Co N.V. Cash And Cash Equivalents At Carrying Value

Quick Answer

NewAmsterdam Pharma Co N.V. reported Cash And Cash Equivalents At Carrying Value of $490.00 million for the year ending 2025.

  • NewAmsterdam Pharma Co N.V. showed a decrease of -36.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), NewAmsterdam Pharma Co N.V.'s Cash And Cash Equivalents At Carrying Value has grown by 43.9%.
  • Historical annual values: Fiscal year 2025: $490.00 million | Fiscal year 2024: $771.74 million | Fiscal year 2023: $340.45 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: